Insider Transactions in Q4 2022 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2022
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.07%
|
$300,000
$15.15 P/Share
|
|
Oct 31
2022
|
Paul Bisaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,875
+50.0%
|
-
|
|
Oct 18
2022
|
Pamela Wong Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,318
-3.05%
|
$66,360
$20.0 P/Share
|
|
Oct 09
2022
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
309
-0.71%
|
$5,871
$19.62 P/Share
|
|
Oct 09
2022
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,385
-1.53%
|
$235,315
$19.62 P/Share
|
|
Oct 09
2022
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,366
-1.78%
|
$158,954
$19.62 P/Share
|
|
Oct 09
2022
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,118
-2.54%
|
$230,242
$19.62 P/Share
|
|
Oct 09
2022
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,926
-1.4%
|
$93,594
$19.62 P/Share
|
|
Oct 09
2022
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,721
-1.98%
|
$32,699
$19.62 P/Share
|